Compassionate use of remdesivir in children with COVID-19

• Published in: European journal of pediatrics 2021-04, Vol.180 (4), p.1317-1322
• Main Authors: Méndez-Echevarría, Ana, Pérez-Martínez, Antonio, Gonzalez del Valle, Luis, Ara, María Fátima, Melendo, Susana, Ruiz de Valbuena, Marta, Vazquez-Martinez, Jose Luis, Morales-Martínez, Antonio, Remesal, Agustín, Sándor-Bajusz, Kinga Amália, Cabañas, Fernando, Calvo, Cristina
• Format: Article
• Language: English
• Subjects: Adenosine Monophosphate - analogs & derivatives; Adenosine Monophosphate - therapeutic use; Adolescent; Adverse events; Alanine - analogs & derivatives; Alanine - therapeutic use; Antiviral Agents - therapeutic use; Antiviral drugs; Child; Child, Preschool; Children; Clinical outcomes; Clinical trials; Compassionate Use Trials; Coronaviruses; COVID-19; COVID-19 - drug therapy; Critical Illness; Female; Humans; Infant; Infants; Male; Medicine; Medicine & Public Health; Pandemics; Patients; Pediatrics; Pharmacokinetics; Sepsis; Severe acute respiratory syndrome coronavirus 2; Severity of Illness Index; Short Communication; Spain; Treatment Outcome
• ISSN: 0340-6199; 1432-1076
• DOI: 10.1007/s00431-020-03876-1

Children represent a minority of total COVID-19 cases, but studies have reported severe disease and death in pediatric patients. Remdesivir (RDV) has recently demonstrated promising results in adults with COVID-19, but few data have been reported to date in children. A nationwide multicenter observational study was conducted on children with confirmed SARS-CoV-2 receiving compassionate treatment with RDV in Spain. Eight patients were included in the study, four infants and four older children [median age 5 years old; IQR 4 months–11.6 years old]. Half of them had complex underlying medical conditions, and the rest were mostly infants (3/4). Six out of eight children needed Pediatric Intensive Care Unit Admission. No RDV-related adverse outcomes were observed in our patients. Seven have reached successful clinical outcome, but one patient with serious clinical status died due to complications. However, she received RDV very late after the first COVID-19 symptom. Conclusions : In our cohort, most of the patients achieved successful clinical outcome, without observing adverse events. Clinical trials of RDV therapy for children with COVID-19 are urgently needed, to assess the safety, tolerability, efficacy, and pharmacokinetics of RDV in children, as this could be an effective treatment in severe cases. What is Known: • Remdesivir has not been approved to treat COVID-19 in children under 12 years old, although the drug is currently being prescribed in critically ill children. • Remdesivir has recently demonstrated promising results in adults with COVID-19, but few data have been reported to date in paediatric population. What is New: • We report a multicentre cohort of children with confirmed SARS-CoV-2 and severe COVID-19 disease receiving remdesivir during the first month of the pandemic in Spain. • No remdesivir-related adverse outcomes were observed in most of the cases. Seven patients reached successful clinical outcome, and one died due to complications (bacterial sepsis).